Quantification of GADD34 Expression in RA
GADD34-RA
1 other identifier
interventional
100
0 countries
N/A
Brief Summary
GADD34 is an inducible cofactor of protein phosphatase 1, which has an important role in the Unfolded Protein Response (UPR). UPR is a cellular response to ER stress which is implicated in several autoimmune diseases. GADD34 has been shown to be necessary for proinflammatory cytokine production in response to viral infection in murine models. Nevertheless, the role of GADD34 in cytokine production in humans remains to be elucidated. Here, we investigate the interest of GADD34 in rheumatoid arthritis (RA), in which proinflammatory cytokines have an important pathogenic role. A case-control study on GADD34 gene expression in PBMC of patients (n=75) with RA and age- and sex-matched healthy controls (n=25). GADD34 gene expression levels in PBMC were measured by quantitative PCR.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable rheumatoid-arthritis
Started Mar 2013
Shorter than P25 for not_applicable rheumatoid-arthritis
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2014
CompletedFirst Submitted
Initial submission to the registry
March 24, 2015
CompletedFirst Posted
Study publicly available on registry
March 27, 2015
CompletedMarch 27, 2015
March 1, 2015
1.2 years
March 24, 2015
March 24, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To determine if GADD34 gene expression level in the PBMC of rheumatoid arthritis patients is increased compared to its expression in the PBMC of healthy controls.
GADD34 gene expression level is quantified in the PBMC by quantitative PCR.
3 years
Secondary Outcomes (4)
To verify the repeatability and reproducibility of GADD34 gene expression quantification by quantitative PCR.
3 years
To compare GADD34 gene expression level in the PBMC of 3 groups of patients: patients with DAS28<2.6 (low RA activity), DAS28>2.6 and <5.1 (intermediate RA activity), DAS28>5.1 (high RA activity).
3 years
GADD34 gene expression in synovial cells.
3 years
GADD34 and cytokine production.
3 years
Study Arms (1)
patient
OTHERpatient
Interventions
Eligibility Criteria
You may qualify if:
- patients with rheumatoid arthritis fulfilling the American College of Rheumatology 1987 revised criteria for the classification of RA
- age between 18 and 75
- patients benefiting of social security
- Informed consent signed by the patients
- groups of patients were included: patients with DAS28\<2.6 (n=25); patients with DAS28\>2.6 and\<5.1 (n=25): patients with DAS28\>5.1 (n=25).
You may not qualify if:
- patients who receive treatments for other pathologies
- persons protected by the law L1121-5 to L1121-8 of CSP (for example: pregnant women)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Clavarino G, Adriouach S, Quesada JL, Clay M, Chevreau M, Trocme C, Grange L, Gaudin P, Gatti E, Pierre P, Cesbron JY, Dumestre-Perard C. Unfolded protein response gene GADD34 is overexpressed in rheumatoid arthritis and related to the presence of circulating anti-citrullinated protein antibodies. Autoimmunity. 2016;49(3):172-8. doi: 10.3109/08916934.2016.1138220. Epub 2016 Feb 1.
PMID: 26829377DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- BASIC SCIENCE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 24, 2015
First Posted
March 27, 2015
Study Start
March 1, 2013
Primary Completion
May 1, 2014
Study Completion
May 1, 2014
Last Updated
March 27, 2015
Record last verified: 2015-03